Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OW9L
|
|||
| Former ID |
DNCL001963
|
|||
| Drug Name |
MK-3134
|
|||
| Indication | Dementia [ICD-11: 6D80-6D86] | Phase 1 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H26F3N3O2
|
|||
| Canonical SMILES |
CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5)C(F)(F)F
|
|||
| InChI |
1S/C25H26F3N3O2/c1-16-29-22-7-3-6-21(25(26,27)28)23(22)24(32)31(16)18-8-10-19(11-9-18)33-20-12-14-30(15-13-20)17-4-2-5-17/h3,6-11,17,20H,2,4-5,12-15H2,1H3
|
|||
| InChIKey |
ZWUFGBNOUKQGBR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 862310-66-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00887601) BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006). U.S. National Institutes of Health. | |||
| REF 2 | Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.